gsk-2636771
Small moleculeexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 10, 2011 (NCT01458067)
Timeline
Indications
Studied for
- Bile Duct Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Glioma · Phase 2
- Kidney Neoplasms · Phase 2
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Skin Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F- Mol. weight
- 433.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3188551 ↗
Also known as
- gsk2636771
- gsk2636771
- gsk2636771
- gsk-2636771
- gsk-2636771
- gsk-2636771
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03131908 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | GlaxoSmithKline, Merck, National Cancer Institute (NCI), National Institutes of Health (NIH), University of Texas at Houston |
| NCT02615730 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2016 | Yonsei University |
| NCT02465060 | Phase 2 | Aug 12, 2015 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT02215096 | Phase 1 | Nov 13, 2014 | GlaxoSmithKline |
| NCT01458067 | Phase 1 | Nov 10, 2011 | GlaxoSmithKline |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 2 | 2 | 2011 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 2015 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2016 |
7 organizations
Page 1 / 1